May 2026
📣 VC round data is live. Check it out!
Largest Biopharmaceuticals Public Companies in China
Benchmark revenue and EBITDA valuation multiples for public comps like
Jiangsu Hengrui Pharma, Hansoh Pharma, Innovent Biologics, Sichuan Biokin and Akeso.
 | Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. | $7 | -8% | $48B | $42B | 9.1x | 30.2x | ||
| Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China. | $4 | +30% | $26B | $21B | 9.7x | 21.0x | ||
| Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt’s main competition include drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Meyers. | $10 | +31% | $18B | $16B | 8.2x | 70.0x | ||
| Sichuan Biokin Pharmaceutical Co Ltd is a chemical drug and biological drug-based company that integrates drug research and development, production and marketing. | $34 | -22% | $14B | $14B | 37.9x | (179.2x) | ||
| Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation, and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China, and also has its presence in USA and Other regions. | $15 | +39% | $14B | $13B | 29.0x | (128.8x) | ||
| Yunnan Baiyao Group Co Ltd is engaged in the manufacturing and marketing of medicines, which include herbal products, daily health products, raw medicine, drug classics, and others. | $7 | -11% | $13B | $11B | 1.8x | 11.6x | ||
| CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C and antibiotics. | $1 | -5% | $11B | $10B | 2.6x | 10.8x | ||
| Zhangzhou Pientzehuang Pharmaceutical Co Ltd produces and sells Chinese medicines. The company's product categories include tablets, hard capsules, granules, pills (water pills, honey pills), syrups, tinctures (including external use), ointments, lozenges, decoctions, Chinese herbal medicine slices (including direct oral slices) (clean preparation); production of candy products (candy), health food products; and production of beverages (solid beverages). | $18 | -38% | $11B | $11B | 8.2x | 27.5x | ||
| WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry. | $7 | +43% | $9B | $8B | 9.4x | 29.5x | ||
| Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries. | $3 | -6% | $8B | $12B | 2.0x | 8.3x | ||
| Haisco Pharmaceutical Group Co Ltd is a pharmaceutical company based in China. It is mainly engaged in the research, development, manufacture, and sale of drugs for liver disease. Its product portfolio includes parenteral nutrition drugs, antibiotics, anesthetic agents, digestive system drugs and tumour adjuvant drug series. The company's products are being used in first rank hospitals in China. | $7 | +12% | $8B | $8B | 12.9x | 97.1x | ||
| RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China. | $15 | +96% | $8B | $8B | 17.1x | 50.5x | ||
| Sichuan Kelun Pharmaceutical Co Ltd is a China-based pharmaceutical company focused on the manufacturing of infusion products, antibiotics, and various medical devices. The company operates its businesses through three segments. The Twinings segment focuses on producing pharmaceutical intermediates. The Botai segment is dedicated to the research, development, manufacturing, and commercialization of medicines. The Other Business segment covers activities such as the development and production of large-volume injections, along with the research, manufacturing, and sales of additional pharmaceutical products and related businesses. | $5 | -10% | $8B | $7B | 2.7x | 12.8x | ||
| Huadong Medicine Co Ltd is engaged in the production and sales of antibiotics, proprietary Chinese medicine, chemical synthetic medicine, and genetic engineering drug products. The company mainly operates its business through three segments. The Manufacturing Business segment is engaged in the research and development, production, and marketing of specialized medicines, medicines for chronic diseases, as well as special medicines. The Commercial Business segment is engaged in the sales of medicines, medical devices, ginseng, and antler pieces. The International Medical Beauty Business segment is engaged in the production and sales of regeneration products, hyaluronic acids, and botulinum toxin products. | $4 | -34% | $8B | $7B | 1.1x | 9.2x | ||
| Beijing Wantai Biological Pharmacy Enterprise Co Ltd is engaged in research, development, production, and sales of in vitro diagnostic reagents, instruments, and vaccines. The company has two segments: Diagnostic and Vaccine. The Diagnostic segment develops and sells in vitro diagnostic reagents such as ELISA, colloidal gold, biochemical, and chemiluminescent kits, along with instruments including chemiluminescent analyzers, fluorescent analyzers, and nucleic acid purification systems. The Vaccine segment focuses on products like the hepatitis E vaccine, the bivalent HPV vaccine, and the nasal spray COVID-19 vaccine. It generates the majority of its revenue from the Diagnostic segment. | $5 | -48% | $7B | $6B | 22.6x | (319.4x) | ||
| 3SBio Inc is a biotechnology company. As a pioneer in the Chinese biotechnology industry, the Group has extensive expertise in researching, developing, manufacturing, and marketing biopharmaceuticals. The core products of the Group include several biopharmaceutical drugs, TPIAO recombinant human erythropoietin rhEPO products EPIAO and SEPO, Yisaipu, Cipterbin, and a small molecule drug, Mandi. Except for minoxidil, an over-the-counter drug, the others are all older-generation biologics. | $2 | +2% | $6B | $4B | 1.4x | 2.2x | ||
| Shanghai Allist Pharmaceuticals Co Ltd is an innovative drug company in the field of cancer treatment. | $13 | -7% | $6B | $6B | 7.2x | 14.5x | ||
| China Resources Sanjiu Medical & Pharmaceutical Co Ltd is a China-based pharmaceutical company. The company operates through three primary segments. The Pharmaceutical Industry segment focuses on manufacturing consumer health (CHC) products, dietary supplements, traditional Chinese medicine health items, and prescription medications. The Printing and Packaging segment handles the design, printing, and packaging of various materials. The Pharmaceuticals, equipment, wholesale, and retail industry segment involves the distribution and sale of pharmaceuticals and medical devices. Products are mainly marketed under the 999 brand, with operations spanning both domestic and international markets. | $4 | -25% | $6B | $6B | 1.2x | 6.1x | ||
| Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalosporins, and bone resorption inhibitors. Its products mainly focus on the areas of cardio-cerebral vascular disease, diabetes, complications, anti-tumor, and orthopedics. Its business lines include high-end chemical drugs, biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other countries and regions. | $5 | -22% | $6B | $6B | 8.6x | 32.4x | ||
| Hebei Changshan Biochemical Pharmaceutical Co Ltd is a biotech high-tech enterprise. It is mainly engaged in the research, development, production, and sale of heparin series products. Some of the company's products are Reserpine sodium, Hyaluronic acid, Heparinoid, Heparin sodium, Tinzaparin sodium, Aspirin enteric-coated tablets, and Yihaitang. | $6 | +9% | $5B | $6B | 45.2x | (209.6x) | ||
| Beijing Tongrentang Co Ltd is a China-based company operating in the traditional Chinese medicinal industry. The company produces modern pharmaceuticals and operates retail businesses and medical services. The company's main products consist of Liuwei Dihuang series, Tongren Dahuoluo series, Tongren Niuhuang Qingxin series, Angong Niuhuang series, and Donkey-hide gelatin series. It distributes its products under the brand of Tongrentang. | $4 | -33% | $5B | $4B | 1.5x | 8.3x | ||
| Shanghai RAAS Blood Products Co Ltd is a blood products manufacturer in China that has a high comprehensive utilization of plasma raw materials and different specifications. It is engaged in the research, development, and manufacture of blood products and plasma-derived medical products. The main products are human albumin, intravenous human immunoglobulin, coagulation factor products, etc. | $1 | -22% | $5B | $5B | 5.0x | 16.8x | ||
| Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others. | $9 | +52% | $5B | $5B | 5.4x | 26.9x | ||
| Shanghai Junshi Biosciences Co Ltd is mainly engaged in innovation-driven biopharmaceutical business. The company's main products include teriprizumab injection, Etesevimab, adalimumab injection, and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases, and infectious diseases. The group’s operations are mainly located in the PRC and the United States of America. | $5 | +11% | $5B | $5B | 13.6x | (54.0x) | ||
| Chongqing Zhifei Biological Products Co Ltd is engaged in research and development, production, and sales of vaccines and biological products. The company's main products include bacterial vaccines for the prevention of meningitis and pneumonia-based bacteria, biological products for the prevention and treatment of tuberculosis, viral vaccines for the prevention of rabies virus, influenza virus, and other viruses, general drugs and other biological products, among others. | $2 | -28% | $5B | $6B | 4.7x | (2.6x) | ||
| Changchun High-Tech Industry (Group) Co Ltd is engaged in the production and sales of biopharmaceuticals, Chinese patent medicine production, and real estate development. The company operates its business through three segments. The Pharmaceuticals segment focuses on the research and development, manufacturing, and sales of genetically engineered biologics, human vaccines, traditional Chinese medicines, and chemical pharmaceuticals. The Real Estate segment is involved in property development and sales. The Services segment provides scientific research and technical support, along with leasing and various business-related services. It generates the majority of its revenue from the Pharmaceuticals segment. | $12 | -23% | $5B | $4B | 2.5x | 37.6x | ||
| Gan and Lee Pharmaceuticals is engaged in Research, development, production and sales of recombinant insulin analog APIs and injections. | $8 | 0% | $5B | $4B | 7.1x | 16.6x | ||
| Dong-E-E-Jiao Co Ltd is a China-based company engaged in the manufacturing and selling of Chinese herbs and traditional Chinese medicines, auxiliary materials for medicine, biological and healthcare products, and genetically engineered medicines. The company's main products include donkey-hide gelatin, compound donkey-hide gelatin paste, donkey-hide gelatin cake, instant donkey-hide gelatin powder, and others. | $7 | -11% | $5B | $3B | 3.3x | 9.9x | ||
| Humanwell Healthcare (Group) Co Ltd is a China-based integrated healthcare solution provider. It provides medicinal products including fertility-regulating drugs, Uyghur medicine, traditional Chinese medicine, medical devices, over-the-counter medicines, anti-infection drugs, herbal medicines, and biological products. The organization has a business presence in China and other international countries. | $3 | -19% | $4B | $5B | 1.3x | 7.4x | ||
| Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products. | $5 | +20% | $4B | $4B | 5.3x | 10.1x | ||
| Shijiazhuang Yiling Pharmaceutical Co Ltd is a China-based company that engages in pharmaceutical manufacturing. The company is principally engaged in the research, development, manufacturing, and sales of traditional Chinese pharmaceutical products, especially in the fields of cardiovascular and cerebrovascular diseases, respiratory diseases, tumors, diabetes, and related complications. Its products include drug series, chemical drugs, Chinese medicine series, and health products. | $2 | +11% | $4B | $4B | 3.1x | 10.9x | ||
| Hubei Jumpcan Pharmaceutical Co Ltd engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemicals based on Chinese traditional medicines, and Chinese medicine health products in China. It offers Chinese and Western medicines in the areas of pediatrics, gynecology, pneumonology, gastroenterology, and geriatrics. The company also develops Chinese and Western medicines in the areas of detoxification, digestive system, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, and hemostasis. | $4 | +8% | $4B | $2B | 2.4x | 6.0x | ||
| Beijing Tiantan Biological Products Corp Ltd uses healthy human plasma and specifically immunized human plasma as raw materials and adopts genetic recombination technology to develop and produce blood products and engage in the blood product business. The company's main products include human albumin, human immunoglobulin (pH4) for intravenous injection, human hepatitis B immunoglobulin, human immunoglobulin, human rabies immunoglobulin, human histamine immunoglobulin, and others. | $2 | -29% | $4B | $4B | 4.0x | 10.9x | ||
| Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases. | $15 | -8% | $4B | $4B | 30.2x | (259.4x) | ||
| China Resources Pharmaceutical is the third-largest medical distributor in China by revenue. It is an integrated pharmaceutical company specializing in research and development, manufacturing, medical distribution, and retail pharmacies. As of 2024, the medical distribution business accounts for 82.8% of its total revenue. CR Pharma’s manufacturing business, 18.0% of total revenue, has subsidiaries with a strong presence in traditional Chinese medicine and consumer healthcare. | $1 | -8% | $4B | $10B | 0.3x | 3.9x | ||
| Livzon Pharmaceutical Group Inc is engaged in China's healthcare sector. As a pharmaceutical manufacturer, the company's portfolio comprises Western pharmaceutical preparations, bulk drugs, traditional Chinese medicines, as well as diagnostic reagents and equipment. Its drug addresses serious conditions such as gastrointestinal, cardiovascular, anti-infectious, antimicrobial, antineoplastic, hemopoietic system, and other conditions. It distributes its products within domestic markets and to overseas markets. It operates in a single reportable segment in the PRC which is pharmaceutical manufacturing. | $4 | -13% | $4B | $3B | 1.5x | 5.3x | ||
| Hualan Biological Engineering Inc is a China-based biopharmaceutical company. It is engaged in the research, development, production, and commercialization of plasma products, viral vaccines, bacterial vaccines, recombinant proteins, and other biologics. The plasma products offered by the company include Human albumin, Human fibrinogen, Human tetanus immunoglobulin, and others. The vaccine products include Recombinant hepatitis B vaccine, Inactivated influenza vaccine, and others. It also offers gene products such as Monoclonal Antibodies for tumor, autoimmune diseases, infectious diseases, transplant rejection, and Recombinant monoclonal antibodies. | $2 | -14% | $4B | $3B | 4.7x | 14.7x | ||
| Brightgene Bio-medical Technology Co Ltd is a pharmaceutical company engaged in research, development and production of new drugs and high-end generic drugs. The company develops macrolides, peptides, polysaccharides, heterocycles, azoles, azines, phenyl ethers, tetracyclines, and production of non-pharmaceutical macrolides, peptides, polysaccharides, heterocycles, azoles, azines, benzene Ethers, tetracyclines. | $8 | +8% | $4B | $4B | 21.0x | 103.9x | ||
| Zhejiang Huahai Pharmaceutical Co Ltd is engaged in research and development, production, and sales of multi-dosage preparations, biological drugs, innovative drugs, and specialty APIs. The company’s products include irbesartan hydrochlorothiazide tablets, losartan potassium tablets, paroxetine hydrochloride tablets, sertraline hydrochloride tablets, linagliptin tablets, dabigatran etexilate capsules, pemetrexed disodium for injection, esomeprazole magnesium enteric-coated capsules, torsemide injection, and others. | $2 | -7% | $3B | $4B | 3.5x | 18.0x | ||
| China Medical System Holdings Ltd is active in the healthcare segment. It is one of the China-based pharmaceutical services companies in the country. The company's business mainly involves the marketing, promotion, and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies. Some of its products include Plendil, Salofalk, Combizym, and others. | $1 | +3% | $3B | $3B | 2.2x | 7.6x | ||
| Xiamen Amoytop Biotech Co Ltd operates as a drug development company. The Company develops and sells protein drugs, interferon drugs, and other products. | $8 | -26% | $3B | $3B | 6.0x | 17.0x | ||
| Walvax Biotechnology Co Ltd is engaged in research and development, production and sales of vaccine products. | $2 | +40% | $3B | $3B | 9.6x | 29.3x | ||
| InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function. | $2 | +8% | $3B | $2B | 16.1x | (52.1x) | ||
| Kangmei Pharmaceutical Co Ltd is a pharmaceutical company engaged in the trading of Chinese herbal medicines, production and sales of Chinese herbal medicine slices, Chinese patent medicine preparations, health foods, chemical drugs, and medical devices, modern pharmaceutical logistics system. The company is also engaged in medical equipment, property leasing and sales, and other services. | $0 | -19% | $3B | $3B | 3.9x | 55.4x | ||
| Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules. | $2 | -13% | $3B | $3B | 2.4x | 10.8x | ||
| Jilin Aodong Pharmaceutical Group Co Ltd is engaged in manufacturing of pharmaceuticals. Its products include Anshen Bunao Liquid, Antelope Cough Syrup, Yangxue Yin Oral Liquid, Xinnao Shutong Capsule, Calf Spleen Extract Injection, Xuefu Zhuyu Oral Liquid, and others. | $3 | +8% | $3B | $3B | 8.7x | 7.5x | ||
| Jiangsu Nhwa Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in the manufacturing of APIs and dosages. The company markets its pharmaceutical products in four main categories: anesthetic drugs, such as midazolam injection and etomidate fat emulsion injection; psychiatric drugs, including risperidone tablets and related products; neurological drugs, such as gabapentin capsules; and bulk pharmaceuticals, including fenofibrate and miconazole nitrate. In addition, the company is also involved in the pharmaceuticals trading business. | $3 | -11% | $3B | $2B | 2.8x | 12.0x | ||
| Betta Pharmaceuticals Co Ltd is a pharmaceutical enterprise that focuses on the research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates in China. | $7 | -14% | $3B | $3B | 6.2x | 20.7x | ||
| Yili Chuannig Biotechnology Co Ltd adopts the most advanced and mature international biological fermentation, chemical extraction, enzymatic hydrolysis, control and energy saving, and environmental protection technology. The main products of the company include erythromycin thiocyanate, cephalosporin intermediates, penicillin intermediates, and crude ursodeoxycholic acid. | $1 | -29% | $3B | $3B | 4.5x | 13.3x | ||
| Apeloa Pharmaceutical Co Ltd is a pharmaceutical company. It is engaged in research and development, manufacturing and marketing of APIs formulations and veterinary drugs. It offers products including Ofloxacin, Levofloxacin Hydrochloride, Marbofloxacin, and others. | $3 | +25% | $3B | $3B | 1.8x | 10.2x | ||
| Sunshine Lake Pharma Co Ltd is a a vertically integrated pharmaceutical company engaging in research and development, production and commercialization of pharmaceutical products. It strategically focus on therapeutic areas of infectious diseases, chronic diseases and oncology. Its existing anti-infective product portfolio mainly includes (i) its top-selling product, Kewei (oseltamivir phosphate), for the treatment of influenza (in particular, Type A and Type B influenza viruses), (ii) one innovative drug developed in-house, Dongweien (emitasvir phosphate), for the treatment of hepatitis C, and (iii) three generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin and Moxifloxacin Hydrochloride. | $5 | -- | $3B | $3B | 5.7x | 60.1x | ||
| Chengdu Kanghong Pharmaceutical Group Co Ltd is a pharmaceutical company. The company is engaged in the research and development, production, and sales of medicine, chemical medicine, and biological products. | $3 | -33% | $3B | $2B | 2.8x | 8.3x | ||
| Sinocelltech Group Ltd is engaged in development and industrialization of biopharmaceutical products such as monoclonal antibodies, recombinant proteins and vaccines. The company has developed technology platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. Its capacities include stable CHO cell line development, cell banking and certification, serum-free and protein-free culture medium development, fed-batch cell culture process development, optimization, and process scale-up; protein purification development, and large scale production. | $6 | +2% | $3B | $3B | 13.0x | (67.6x) | ||
| Joincare Pharmaceutical Group Industry Co Ltd is an integrated pharmaceutical company, the business scope covers healthcare products, APIs, final dosage forms, prescription drugs, OTCs, Chinese traditional medicine, chemical drugs, and testing agents. APIs are antibiotic series and their intermediates 7ACA, 4AA and F9. Prescription drugs focus on the realms of the digestive tract, a blood vessel of heart and brain, infection, tumor, nervous cerebrovascular section, urinary system etc. OTCs include gastrointestinal drug Dele-Livzon, Live Bifidobacterium Preparation, oral ulcer drugs Yiketie, cold medicine Antiviral Oral Granule, External use skin medicine. | $1 | -9% | $3B | $1B | 0.6x | 2.0x | ||
| China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas. | $2 | -13% | $3B | $2B | 1.5x | 5.9x | ||
| Duality Biotherapeutics Inc is a key player in the antibody-drug conjugate (ADC) landscape, dedicated to the development of inventive therapeutics in this fast-growing drug modality to treat cancer, autoimmune diseases, and beyond. Its pipeline of 12 in-house discovered ADC candidates is a testament to its prowess in ADC innovation, comprising: (i) seven clinical-stage ADCs with potential in a broad range of indications, two next-generation bispecific ADCs, and multiple other preclinical ADCs. Its Products DB-1303/BNT323 and DB-1311/BNT324 and key product DB-1305/BNT325, have received Fast Track Designation. DB-1303 is a late clinical-stage HER2 ADC candidate with two ongoing registrational trials and one potential global registrational study. | $28 | +6% | $3B | $2B | 7.6x | (29.9x) | ||
| BeBetter Med Inc is a biopharmaceutical company based in China, focusing on independent research and development of drugs. The company focuses on developing novel medicines for treating cancers, autoimmune diseases, and other severe conditions. Key products include the PI3K/HDAC dual inhibitor BEBT-908 and multiple drugs in clinical trial phases targeting cancers. It’s a United States subsidiary BeBetter Pharma specializes in next-generation siRNA therapeutics using proprietary delivery platforms aimed at complex diseases like kidney disorders, metabolic and liver diseases, and neurodegenerative conditions. Its pipeline includes oral and injectable drug candidates, some in late-stage trials, and aims to address unmet medical needs through novel mechanisms. | $6 | -- | $2B | $2B | — | (108.8x) | ||
| Grand Pharmaceutical Group Ltd, is an international pharmaceutical company of technological innovation. Its core businesses cover three areas: nuclear medicine anti-tumor diagnosis and treatment, cerebro-cardiovascular precision interventional diagnosis and treatment technology, pharmaceutical technology, and biotechnology. Based on the pharmaceutical and biological industries, the Group focuses on the needs of patients, and technological innovation as the driving force Geographically, it derives a majority of its revenue from the PRC and also has a presence in America; Europe; and Asia other than the PRC, and others. | $1 | -36% | $2B | $3B | 1.8x | 9.8x | ||
| Shandong Buchang Pharmaceuticals Co Ltd is engaged in research and development, production and sales of Chinese patent medicines. | $2 | -7% | $2B | $3B | 1.6x | 16.0x | ||
| Shenzhen Kangtai Biological Products Co Ltd is a human vaccine research and development company. The company is engaged in the research and development, production and sales of recombinant hepatitis B vaccine, b -type influenza Haemophilus conjugate vaccine, measles-rubella combined live attenuated vaccine, cell-free baibai broke b Haemophilus influenzae vaccine and other products. | $2 | -4% | $2B | $2B | 5.7x | 24.4x | ||
| TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its Core Product Tinengotinib is a unique multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China. | $5 | -- | $2B | $2B | — | (49.9x) | ||
| Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion. | $3 | -14% | $2B | $2B | 6.7x | 13.6x | ||
| Jinyu Bio-Technology Co Ltd is engaged in the development and sales of veterinary biological products. Its products are used for pigs, poultry, pets, and ruminants. | $2 | +81% | $2B | $2B | 9.3x | 35.8x | ||
| HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures. | $2 | -13% | $2B | $815M | 1.5x | 1.6x | ||
| Anhui Anke Biotechnology (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceuticals and health-care products. The Company distributes its product in both domestic and overseas markets. The company operates in more than 30 provinces in China. | $1 | -4% | $2B | $2B | 4.7x | 13.0x | ||
| Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China. | $5 | -17% | $2B | $2B | 22.6x | (11.9x) | ||
| Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business, and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from USA and Europe. | $1 | -13% | $2B | $2B | 2.4x | 15.6x | ||
| Nanjing King-Friend Biochemical Pharmaceutical Co Ltd is a China-based company engaged in the research and development, import and export of medicines and health products. The main products of the company are Heparin sodium and low molecular weight heparin. Geographically, the business activities are carried out through China and it exports the product mainly to the European and American countries. | $1 | -26% | $2B | $2B | 3.1x | 12.6x | ||
| Mabwell (Shanghai) Bioscience Co Ltd is engaged in the research and development, production and sales of therapeutic biological products. | $4 | +23% | $2B | $2B | 22.0x | (22.5x) | ||
| Yifan Pharmaceutical Co Ltd is a China-based company engaged in R&D and production company focusing on the pharmaceutical and health sectors. Its vision is to develop drugs with definite clinical values, to help disease-afflicted patients regain health. The group focuses on four business areas such as biologics, small molecules, synthetic biologics, and special traditional Chinese medicines (TCMs). The products of the company are Ryzneuta, Plerixafor Injection, Vincristine Sulfate, Skin Allergy Reli, and Others. | $2 | -21% | $2B | $2B | 2.7x | 16.0x | ||
| Tibet Cheezheng Tibetan Medicine Co Ltd is Tibetan medicine manufacturer. It is mainly engaged in the research, development, production, and sales of Tibetan medicines. The company's products include medicines such as emplastrum, ointments, granules, pills, and powders. | $3 | -10% | $2B | $2B | 4.4x | 11.4x | ||
| Guobang Pharma Ltd is engaged in the research and development, production and sales of related products in the field of medicine and animal health products. | $3 | -- | $2B | $2B | 1.8x | 6.5x | ||
| Zhejiang Wolwo Bio-Pharmaceutical Co Ltd is a Chinese bio-pharmaceutical company. It is engaged in the research development, production and sales of allergic diseases diagnosis and treatment products. The product portfolio of the company covers dust mites drops, dust mites skin prick diagnosis kit, silk, and others. | $3 | +15% | $2B | $2B | 10.0x | 21.7x | ||
| Pacific Shuanglin Bio-pharmacy Co Ltd is engaged in the research, development, production, and marketing of blood products. | $2 | -28% | $2B | $2B | 4.4x | 17.6x | ||
| InventisBio Co Ltd is an innovative drug research and development enterprise based in China with a global perspective, focusing on major diseases such as tumors and metabolic diseases. It has independently developed a series of innovative targeted drugs with patent protection, covering non-small cell lung cancer, breast cancer, colorectal cancer and other solid tumors, as well as hyperuricemia and metabolic diseases such as gout. | $3 | -35% | $2B | $1B | 268.4x | (33.2x) | ||
| Hualan Biological Vaccine Inc is engaged in Research, development, production and sales of human vaccines. | $3 | +14% | $2B | $1B | 7.8x | 28.1x | ||
| CStone Pharmaceuticals is engaged in developing and commercializing of immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. | $1 | +103% | $2B | $2B | 39.1x | (28.8x) | ||
| Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications. | $4 | +2% | $2B | $1B | 43.3x | (23.0x) | ||
| Yantai Dongcheng Biochemicals Co Ltd is a biochemical analytical profile index (API) manufacturers in China. In addition, the company also focuses on the development of finished preparation which covers the therapeutic area of cardiovascular, oncology, orthopedics, and anti-infection. Its product offering includes heparin sodium, chondroitin sulfate, marine collagen, hyaluronic acid, glucosamine, heparinoids, and cytochrome C. The company's API products have been exported to more than fifty countries and regions, including the United States of America, Germany, Austria, and Japan. | $2 | -14% | $2B | $1B | 3.7x | 17.0x | ||
| Ab&B Bio-Tech Co Ltd JS is a China-based vaccine company dedicated to the research, development, manufacturing and commercialization of innovative vaccines and traditional vaccines adopting new technical methods. Its pipeline included two Core Products, the quadrivalent subunit influenza vaccine and lyophilized human rabies vaccine candidate, along with 11 other vaccine candidates. | $4 | -- | $1B | $2B | 41.6x | (59.5x) | ||
| Sinopep Allsino Bio Pharmaceutical Co Ltd is a market-oriented, research and development and innovation-driven biomedical enterprise focusing on the research, development, production and sales of peptide drugs and small molecule chemical drugs. | $5 | -8% | $1B | $2B | 6.0x | 15.6x | ||
| Zhejiang Jolly Pharmaceutical Co Ltd is a China-based company engaged in the production and distribution of pharmaceutical products. Its production lines include raw materials, tablets, capsules, particles and frozen dry powder injection. Its products include Wuling powder, Wuling capsule, linglianhua particle, clindamycin phosphate injection and other. | $2 | -11% | $1B | $1B | 3.2x | 11.6x | ||
| Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others. Geographically operates in Mainland China. | $4 | -28% | $1B | $1B | 4.6x | (20.9x) | ||
| Liaoning Chengda Biotechnology Co Ltd is engaged in the research and development, production and sales of human vaccines. | $3 | -14% | $1B | $612M | 3.0x | 11.9x | ||
| HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States. | $2 | +36% | $1B | $975M | 6.2x | 9.9x | ||
| Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation. | $7 | +20% | $1B | $1B | 5.4x | 18.2x | ||
| Star Lake Bioscience Co Inc is a China-based Pharmaceutical manufacturer. The company is mainly engaged in the research, development, production, and sales of chemical raw materials and pharmaceutical intermediates. Products offered by the company include proline, guanosine, adenosine, adenine, adefovir dipivoxil, memantine hydrochloride, Proline, threonine, lysine, among others. Its products are used in food processing, feed processing, and pharmaceutical manufacturing. Star Lake sells its products through direct sales and distributors in China and overseas markets. | $1 | -28% | $1B | $2B | 0.9x | 6.4x | ||
| Youcare Pharmaceutical Group Co Ltd is a pharmaceutical group enterprise integrating new drug research and development, drug production, circulation and sales. | $3 | +38% | $1B | $1B | 3.2x | (1079.9x) | ||
| Jiangxi Fushine Pharmaceutical Co Ltd is engaged in research and development, manufactures and sells APIs and pharmaceutical intermediates. It offers penicillin, carbapenem, and other products. | $2 | +68% | $1B | $1B | 7.8x | 57.4x | ||
| Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products. | $1 | +11% | $1B | $1B | 9.6x | 34.4x | ||
| Bio-Thera Solutions Ltd is engaged in research, development, and production of drugs and biosimilars. The company provides drug research and development; biotechnology consulting and communication services; services; medical research and experimental development; biological drug manufacturing; and pharmaceuticals retail. | $3 | -24% | $1B | $1B | 9.3x | (41.9x) | ||
| Guilin Sanjin Pharmaceutical Co Ltd is engaged in research and development of proprietary Chinese medicines and natural medicines. | $2 | -4% | $1B | $976M | 3.2x | 10.1x | ||
| GuangYuYuan Chinese Herbal Medicine Co Ltd distributes pharmaceutical products. Its products include far plate turtle age wine bottle, niuhuang qingxin pills, boutique angong niuhuang wan, modified turtle age wine, ding kundan, and many more. | $2 | -30% | $1B | $1B | 5.1x | 45.1x | ||
| Lepu Biopharma Co Ltd is a biopharmaceutical company focusing on oncology therapeutics and has one operating segment. The Group is principally engaged in the sales of pharmaceutical products and the research and development of new drugs. The majority operating entity of the Group is domiciled in Mainland China. The company has established an integrated end-to-end platform across drug discovery, clinical development, CMC, and GMP-compliant manufacturing, encompassing all critical functions of the biopharmaceutical value chain. The company generates the majority of its revenue from the Sale of pharmaceutical products. The company also generates a small portion of its revenue from Licensing income. | $1 | +2% | $1B | $1B | 7.8x | 19.0x | ||
| Acrobiosystems Co Ltd is a global brand focusing on protein technology, products and services in the development of biological drugs. It is committed to providing target antigens and other key reagents and related services required in the development of targeted therapeutic drugs. | $6 | +14% | $1B | $857M | 6.9x | 24.2x | ||
| China Traditional Chinese Medicine Holdings Co Ltd is engaged in the Chinese healthcare sector. The company functions through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. It generates maximum revenue from the Yifang segment which mainly engages in the manufacture and sales of concentrated TCM granules (CTCMG), TCM healthcare products, and TCM decoction pieces under the Yi Fang brand. The majority of the revenue of the Yi Fang segment is derived from the sales of CTCMG. Geographically, it derives a majority of its revenue from Mainland China, and also has its presence in Hong Kong and Other countries. | $0 | -29% | $1B | $653M | 0.3x | 4.4x | ||
| Changchun BCHT Biotechnology Co is a biopharmaceutical enterprise specializing in the research and development, production and sales of human vaccines. | $2 | -20% | $1B | $1B | 11.5x | (38.7x) | ||
| Wuhan Keqian Biology Co Ltd is engaged in research and development, production, sales and animal epidemic prevention technical services of veterinary biological products. The company's products include Combination plan; Vaccine for swine; Poultry vaccine; Pet vaccine; and Diagnostic reagent. | $2 | -16% | $973M | $698M | 5.0x | 8.0x | ||
| Chengdu Kanghua Biological Products Co Ltd is engaged in research, development, production, sales and technical services of biological products for prevention, and the existing products include Group ACYW135 Meningococcal Polysaccharide Vaccine-Maikexin, Rabies Vaccine (human diploid cell) for Human Use, freeze-dried - HDCV. The company's products include ACYW135 Meningococcal Polysaccharide Vaccine; and Rabies Vaccine. | $7 | -11% | $966M | $815M | 4.8x | 16.2x | ||
| Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine. | $2 | +24% | $888M | $937M | 3.7x | 41.6x | ||
| Median | $3 | -8% | $3B | $3B | 5.0x | 10.9x |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Recent Insights
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.